FindTrial
Sign In

CLINICAL TRIAL OF HELICAL TOMOTHERAPY (HT) VERSUS THREE-DIMENSIONAL CRT(3DCRT) IN HCC WITH MACROVASCULAR INVASION

CLINICAL TRIAL OF HELICAL TOMOTHERAPY (HT) VERSUS THREE-DIMENSIONAL CRT(3DCRT) IN HCC WITH MACROVASCULAR INVASION

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OCH-14004809
Enrollment
Unknown
Registered
2014-05-15
Start date
2014-06-16
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Hepatocellular cancer

Interventions

1:tomotherapy
2:THREE-DIMENSIONAL CRT(3DCRT)

Sponsors

Zhongshan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Aged 18-70 years; KPS>80;Absence of radiation to abdomen history; HCC (biospy or radiological diagnostic guidelines); Major vascular invasion without extrahepatic metastasis; Child-pugh A/B; Blood test: WBC>2X109/LHb> 90g/LPLT>100X10^9/L; Creatinine, urea nitrogen normal; Signed informed consent.

Exclusion criteria

Exclusion criteria: Child-pugh C; The volume of normal liver<700cc; Extrahepatic metastasis; Active hepatitis; Severe gastrointestinal diseases,such as gastrointestinal bleeding; Secondary cancer; Pregnancy; Refuse radiation.

Design outcomes

Primary

MeasureTime frame
OS;—

Contacts

Public ContactHou Jiazhou

Zhongshan Hospital, Fudan University

hou.jiazhou@zs-hospital.sh.cn+86 18116313252

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026